Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study
Pembrolizumab continued to show durable response and manageable safety in participants with advanced HCC with or without prior systemic therapy, with long-term effects on OS lasting beyond 48 months in some participants despite receiving study treatment for ≤2 years.
Authors
- Bruno Daniele
- Ken Hatogai (ORCID: https://orcid.org/0000-0001-7888-7965)
- Julien Edeline (ORCID: https://orcid.org/0000-0002-8289-7741)
- Richard S. Finn (ORCID: https://orcid.org/0000-0003-2494-2126)
- Amos Odeleye-Ajakaye
- Per Stål (ORCID: https://orcid.org/0000-0002-9340-5298)
- Sadahisa Ogasawara (ORCID: https://orcid.org/0000-0002-6540-9064)
- Stéphane Cattan
- Abby B. Siegel
- Stephen Lam Chan
- Ivan Borbath
- A. Vogel
- Ann-Lii Cheng
- Jennifer J. Knox
- Masatoshi Kudo
- Daniel Palmer
- Jean-Luc Van Laethem
- Chris Verslype
- Hans van Vlierberghe
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Cliniques Universitaires Saint-Luc (BE)
- Université Libre de Bruxelles (BE)
- Chiba University (JP)
- University of California, Los Angeles (US)
- National Taiwan University (TW)
- Chinese University of Hong Kong (HK)
- Princess Margaret Cancer Centre (CA)
- Karolinska Institutet (SE)
- Clatterbridge Cancer Centre NHS Foundation Trust (GB)
- Ghent University (BE)
- Medizinische Hochschule Hannover (DE)
- Kindai University Hospital (JP)
- Centre Eugène Marquis (FR)
- Prince of Wales Hospital (CN)
- National Taiwan University Hospital (TW)
- Ospedale D. Cotugno (IT)
- Hôpital Claude Huriez (FR)
- Kindai University (JP)
- KU Leuven (BE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3528
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00